GlassScriptPhysician profile
Magdala Paul
NPI 1992103469
$1,668.80
in general payments reported to CMS, 2019-2025
25 companies · $902 in 2025
The $902 reported for 2025 was more than what 87% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $62.66 · 2024: $705 · 2025: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,606.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $181.63 | 2024-2025 | |
| Lilly USA, LLC | $170.83 | 2024-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $157.40 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $145.38 | 2021-2025 | Airsupra |
| Sumitomo Pharma America, INC. | $119.70 | 2024-2025 | Gemtesa |
| Amgen INC. | $115.05 | 2024-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $100.77 | 2024-2025 | Freestyle Libre |
| Insmed, INC. | $76.08 | 2025 | Brinsupri, Arikayce |
| Exact Sciences Corporation | $72.34 | 2025 | The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.85 | 2024-2025 | Xifaxan |
| Astellas Pharma US INC | $50.73 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $46.11 | 2024-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.13 | 2024-2025 | Jardiance, Synjardy |
| Esperion Therapeutics, INC. | $42.86 | 2024-2025 | Nexletol |
| Abbvie INC. | $36.51 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $34.56 | 2024-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $31.68 | 2024 | |
| Janssen Pharmaceuticals, INC | $27.34 | 2021 | |
| Gilead Sciences, INC. | $25.93 | 2025 | |
| Alnylam Pharmaceuticals INC. | $22.45 | 2025 | Onpattro |
| Sanofi-Aventis U.S. LLC | $22.24 | 2024 | |
| Phathom Pharmaceuticals, INC. | $20.00 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $19.99 | 2024 | |
| Eagle Pharmaceuticals, INC. | $19.79 | 2024 | |
| Csl Behring | $17.45 | 2025 | Andembry |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Magdala Paul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.